AC Immune SA

3.47-0.1700-4.67%Vol 20.50K1Y Perf -43.91%
Aug 16th, 2022 16:00 DELAYED
BID3.11 ASK3.52
Open3.58 Previous Close3.64
Pre-Market- After-Market3.47
 - -  - -%
Target Price
11.33 
Analyst Rating
Strong Buy 1.00
Potential %
226.51 
Finscreener Ranking
★★★+     50.29
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.02
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
13.36 
Earnings Rating
Sell
Market Cap289.44M 
Earnings Date
3rd Aug 2022
Alpha-0.01 Standard Deviation0.17
Beta0.71 

Today's Price Range

3.403.60

52W Range

2.0612.61

5 Year PE Ratio Range

-43.9019.70

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.87%
1 Month
3.27%
3 Months
11.94%
6 Months
-22.37%
1 Year
-43.91%
3 Years
-35.50%
5 Years
-52.85%
10 Years
-

TickerPriceChg.Chg.%
ACIU3.47-0.1700-4.67
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
-
-7 498.60
-7 255.50
-320.00
-51.92
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-26.85
-12.76
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.24-0.240.00
Q01 2022-0.23-0.25-8.70
Q04 2021--0.28-
Q03 2021-0.29-0.2417.24
Q02 2021-0.22-0.29-31.82
Q01 2021-0.21-0.25-19.05
Q04 2020-0.29-0.30-3.45
Q03 2020-0.24-0.28-16.67
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.240.00-
9/2022 QR-0.240.00-
12/2022 FY-0.99-1.02Negative
12/2023 FY-0.342.86Positive
Next Report Date-
Estimated EPS Next Report-0.24
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume20.50K
Shares Outstanding83.41K
Shares Float39.31M
Trades Count289
Dollar Volume71.84K
Avg. Volume56.51K
Avg. Weekly Volume35.66K
Avg. Monthly Volume51.00K
Avg. Quarterly Volume82.86K

AC Immune SA (NASDAQ: ACIU) stock closed at 3.47 per share at the end of the most recent trading day (a -4.67% change compared to the prior day closing price) with a volume of 20.50K shares and market capitalization of 289.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 132 people. AC Immune SA CEO is Andrea Pfeifer.

The one-year performance of AC Immune SA stock is -43.91%, while year-to-date (YTD) performance is -29.9%. ACIU stock has a five-year performance of -52.85%. Its 52-week range is between 2.06 and 12.61, which gives ACIU stock a 52-week price range ratio of 13.36%

AC Immune SA currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 1.32, a price-to-sale (PS) ratio of 212.87, a price to cashflow ratio of 8.90, a PEG ratio of 2.32, a ROA of -34.82%, a ROC of -39.85% and a ROE of -38.01%. The company’s profit margin is -51.92%, its EBITDA margin is -7 255.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AC Immune SA, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. AC Immune SA’s next earnings report date is -.

The consensus rating of Wall Street analysts for AC Immune SA is Strong Buy (1), with a target price of $11.33, which is +226.51% compared to the current price. The earnings rating for AC Immune SA stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AC Immune SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AC Immune SA has a Buy technical analysis rating based on Technical Indicators (ADX : 37.64, ATR14 : 0.26, CCI20 : 177.20, Chaikin Money Flow : 0.20, MACD : 0.04, Money Flow Index : 83.53, ROC : 3.12, RSI : 60.71, STOCH (14,3) : 98.15, STOCH RSI : 0.98, UO : 51.09, Williams %R : -1.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AC Immune SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

CEO: Andrea Pfeifer

Telephone: +41 216939121

Address: EPFL Innovation Park, Lausanne 1015, , CH

Number of employees: 132

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

65%35%

Bearish Bullish

65%35%


News

Stocktwits